MetrioPharm Press Releases
Long-term Toxicology Studies Confirm Very Good Safety Profile of MP1032
MetrioPharm AG reports positive results from two long-term preclinical toxicology studies in the rat and the dog.
MetrioPharm AG Announces Change In Management Team
MetrioPharm AG announces that Sven Zimmermann will leave the company as of March 31, 2021. Sven Zimmermann was the CFO of MetrioPharm AG since August 2019.
COVID-19 Therapeutic Agent: MetrioPharm Prepares to Conduct a Phase II Clinical Trial
Following positive data from pre-clinical studies published in the peer-reviewed International Journal of Molecular Science, the company believes that MP1032 has the potential to both, slow down the spread of the virus in the body, and alleviate COVID-19 symptoms.
MetrioPharm Announces Publication of Successful MP1032 Preclinical Data in COVID-19
MetrioPharm AG announces the publication of preclinical data showing its lead compound MP1032 could be a promising option for prevention and treatment of the SARS-CoV-2-induced cytokine storm.
MetrioPharm Successfully Completes Study in COPD Model
MetrioPharm is now exploring the development of the MP1000 platform in an inhaled dosage form.
MetrioPharm AG Phase II Data in Psoriasis Show Dose-Response
The data confirm the trend towards clinical efficacy and outstanding safety profile of MP1032, the lead compound from a new class of proprietary immune modulators developed by MetrioPharm AG.
Sven Zimmermann Joins MetrioPharm Management as CFO
MetrioPharm AG, welcomes Sven Zimmermann, as its new Chief Financial Officer, bringing more than a decade of experience in strategic transactions.
Last Patient Last Visit in MetrioPharm’s Phase II Clinical Trial in Psoriasis
MetrioPharm AG announces that the last patient was now examined during the currently ongoing clinical psoriasis Phase II study (Last Patient Last Visit).
MetrioPharm AG Publishes Annual Report for 2018
Financing round D for 20 million CHF was closed, Phase II clinical trial successfully initiated, Focus of the report: InflammAging.
MetrioPharm AG welcomes Barry Frankel as a new team member
He will be responsible for the future development strategy and Business Development. Negotiations with potential pharmaceutical partners will be a focus of his work.